Boston Scientific (NYSE: BSX) is expected to report Q3 earnings on Oct. 18. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Boston Scientific's revenues will drop -5.6% and EPS will increase 10.0%.

The average estimate for revenue is $1.77 billion. On the bottom line, the average EPS estimate is $0.11.

Revenue details
 Last quarter, Boston Scientific reported revenue of $1.83 billion. GAAP reported sales were 7.4% lower than the prior-year quarter's $1.98 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.11. GAAP EPS were -$2.51 for Q2 compared to $0.10 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 65.9%, 280 basis points better than the prior-year quarter. Operating margin was 13.5%, 100 basis points worse than the prior-year quarter. Net margin was -195.7%, 20,310 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $7.28 billion. The average EPS estimate is $0.42.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 751 members out of 936 rating the stock outperform, and 185 members rating it underperform. Among 187 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 166 give Boston Scientific a green thumbs-up, and 21 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.84.